The Role of PIK3CA Mutations among Lung Adenocarcinoma Patients with Primary and Acquired Resistance to EGFR Tyrosine Kinase Inhibition

Podobné jednotky

• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  Autor: Shang-Gin Wu, a další
  Vydáno: (2017-07-01)
• Lung adenocarcinoma patients of young age have lower EGFR mutation rate and poorer efficacy of EGFR tyrosine kinase inhibitors
  Autor: Wu, Shang-Gin, a další
  Vydáno: (2017)
• The mechanism of acquired resistance to irreversible EGFR tyrosine kinase inhibitor-afatinib in lung adenocarcinoma patients
  Autor: Wu, Shang-Gin, a další
  Vydáno: (2016)
• Acquired Gefitinib-Resistant Mutation of EGFR in a Chemonaive Lung Adenocarcinoma Harboring Gefitinib-Sensitive Mutation L858R
  Autor: Gow, Chien-Hung, a další
  Vydáno: (2005)
• Impact of concurrent PIK3CA mutations on response to EGFR tyrosine kinase inhibition in EGFR-mutant lung cancers and on prognosis in oncogene-driven lung adenocarcinomas
  Autor: Eng, Juliana, a další
  Vydáno: (2015)